| The effect of glucagon-like peptide-2 on arterial blood flow and cardiac parameters. | |
| | |
MedLine Citation:
|
PMID: 19900491 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Glucagon-like peptide-2 (GLP-2) is known to increase mesenteric blood flow. The aim of the study was to evaluate the effect of GLP-2 on blood flow in different vascular sites, and dynamic changes in cardiac parameters. METHODS: 10 healthy volunteers were given 450 nmol subcutaneous (SC) GLP-2 or isotonic saline (5 subjects) in a single blinded manner. During the following 90 min, blood flow in the superior mesenteric artery (SMA), celiac artery (CA), renal artery (RA), common carotid artery (CCA) was measured using Doppler ultrasound (US), and cardiovascular variables were measured by impedance cardiography and finger plethysmography. Plasma GLP-2 was measured at times 0, 30 and 60 min. RESULTS: Compared to the placebo group, GLP-2 elicited a 27% decrease in the resistance index (RI) and a 269.4% increase in Time Averaged Maximal Velocity (TAMV) in the SMA (P<0.01). CA, RA and CCA: There were no significant changes in RI or TAMV in the GLP-2 or placebo group, and no change in CA diameter. Cardiac parameters: GLP-2 increased cardiac output (CO), stroke volume (SV) and heart rate (HR) compared to baseline (respectively: 15.3, 4.81 and 8.2% (P<0.001, P<0.01 and P<0.01)). The CO, SV and HR changes were not significantly different from the placebo group. Mean plasma GLP-2 serum levels in the placebo group at times 0, 30 and 60 min were 22.8, 23.4 and 23.2 pmol/l. In the GLP-2 group 20.3, 1273 and 1725 pmol/l. CONCLUSION: SC GLP-2 increased SMA blood flow, as previously shown, but elicited no changes in other vascular sites. CO and HR increased significantly, presumably due to the increased mesenteric blood flow. |
| | |
Authors:
|
Lasse Bremholm; Mads Hornum; Ulrik B Andersen; Jens Juul Holst |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Regulatory peptides Volume: 159 ISSN: 1873-1686 ISO Abbreviation: Regul. Pept. Publication Date: 2010 Jan |
Date Detail:
|
Created Date: 2009-12-17 Completed Date: 2010-02-23 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8100479 Medline TA: Regul Pept Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 67-71 Citation Subset: IM |
Affiliation:
|
Department of Gastroenterology, Glostrup Hospital, University of Copenhagen, Denmark. Hoersted-bremholm@webspeed.dk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Blood Flow Velocity / drug effects Cardiography, Impedance Female Glucagon-Like Peptide 2 / pharmacokinetics, pharmacology* Heart Rate / drug effects* Humans Male Single-Blind Method Splanchnic Circulation / drug effects* Stroke Volume / drug effects* Ultrasonography, Doppler Vascular Resistance / drug effects* |
| Chemical | |
Reg. No./Substance:
|
0/Glucagon-Like Peptide 2 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Gel free analysis of the Proteome of intracellular Leishmania mexicana.
Next Document: The protective effects of calcitonin gene-related peptide on gastric mucosa injury after cerebral is...